S Bank Fund Management Ltd Sells 11,977 Shares of Royalty Pharma PLC $RPRX

S Bank Fund Management Ltd trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 27.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 30,972 shares of the biopharmaceutical company’s stock after selling 11,977 shares during the period. S Bank Fund Management Ltd’s holdings in Royalty Pharma were worth $1,197,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Strs Ohio lifted its stake in Royalty Pharma by 2.8% in the 4th quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 252 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Royalty Pharma by 0.6% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock worth $1,673,000 after purchasing an additional 255 shares during the last quarter. CWM LLC increased its holdings in shares of Royalty Pharma by 1.5% in the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 281 shares during the last quarter. Private Trust Co. NA lifted its position in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 288 shares in the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in shares of Royalty Pharma by 1.0% in the third quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock worth $1,037,000 after buying an additional 289 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Terrance P. Coyne sold 34,791 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,164 shares of company stock worth $6,624,902 in the last ninety days. 18.84% of the stock is owned by insiders.

Royalty Pharma Trading Up 0.5%

Shares of RPRX opened at $50.44 on Wednesday. The company’s fifty day simple moving average is $47.42 and its 200-day simple moving average is $42.56. The company has a market cap of $29.10 billion, a P/E ratio of 37.36, a P/E/G ratio of 3.21 and a beta of 0.40. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a twelve month low of $31.97 and a twelve month high of $50.82.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. As a group, analysts expect that Royalty Pharma PLC will post 5.08 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s payout ratio is 69.63%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on RPRX shares. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. UBS Group upped their price objective on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Finally, Citigroup boosted their price target on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus target price of $50.33.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.